{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:32:42Z","timestamp":1783769562440,"version":"3.55.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Cancer Center Support"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01-CA199338, R01CA244948"],"award-info":[{"award-number":["U01-CA199338, R01CA244948"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Prostate Cancer Foundation"},{"name":"Prostatacancerf\u00f6rbundet"},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["21 1629 Pj 01 H"],"award-info":[{"award-number":["21 1629 Pj 01 H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Scientific Council","award":["2023-02671"],"award-info":[{"award-number":["2023-02671"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We investigated the natural history of the relationship between prostate-specific antigen (PSA) at age 60 years and lifetime risk of prostate cancer death in an unscreened cohort followed for 40\u2009years in the Malm\u00f6 Preventive Project. We also investigated whether percent-free PSA could risk-stratify men with low PSAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The cohort included 1162 men aged 58-62 years at blood draw in 1981-1982, with 1151 deaths by December 31, 2020. Total and free PSA were measured for 130 men with prostate cancer and 517 without prostate cancer. Lorenz curves were calculated for life years lost to prostate cancer by baseline PSA level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Total PSA at age 60 years remained highly predictive for full lifetime risk of lethal prostate cancer (C index = 0.87, 95% confidence interval [CI] = 0.82 to 0.92). More than half of the life years lost to prostate cancer in this cohort were in men who had a PSA above 4.0\u2009ng\/ml (59%, 95% CI = 54% to 63%) at age 60 years, with 85% (95% CI = 81% to 89%) and 92% (95% CI = 90% to 94%) in men with a PSA above 2.0\u2009ng\/ml and above 1.0\u2009ng\/ml, respectively. Percent-free PSA did not aid risk stratification in men with low PSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Men with a PSA below 1-2\u2009ng\/ml at age 60 years are at low risk for lethal prostate cancer and do not require further PSA screening. Unlike a proven role in men with elevated PSA, percent-free PSA is not useful in informing the decision to stop or continue further PSA screening for men with a PSA below 2\u2009ng\/ml at age 60 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf271","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:07:54Z","timestamp":1758110874000},"page":"2591-2597","source":"Crossref","is-referenced-by-count":3,"title":["Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6948-9850","authenticated-orcid":false,"given":"Emily A","family":"Vertosick","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-6503","authenticated-orcid":false,"given":"Andrew","family":"Vickers","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Dahlin","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Lund University , Malm\u00f6,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ulmert","sequence":"additional","affiliation":[{"name":"Department of Molecular & Medical Pharmacology, University of California Los Angeles , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid V","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]},{"name":"Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]},{"name":"Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg ,","place":["Sweden"]},{"name":"Department of Translational Medicine, Division of Urological Cancers, Medical Faculty, Lund University , Lund,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Eastham","sequence":"additional","affiliation":[{"name":"Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-3786","authenticated-orcid":false,"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Division of Urological Cancers, Medical Faculty, Lund University , Lund,","place":["Sweden"]},{"name":"Department of Urology, Sk\u00e5ne University Hospital , Malm\u00f6,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-7846","authenticated-orcid":false,"given":"Hans","family":"Lilja","sequence":"additional","affiliation":[{"name":"Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]},{"name":"Departments of Pathology and Laboratory Medicine, and Medicine (GU-Oncology Service), Memorial Sloan Kettering Cancer Center , New York, NY,","place":["United States"]},{"name":"Department of Translational Medicine, Lund University , Malm\u00f6,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2025120718571697500_djaf271-B1"},{"key":"2025120718571697500_djaf271-B2","doi-asserted-by":"crossref","first-page":"g2296","DOI":"10.1136\/bmj.g2296","article-title":"Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study","volume":"348","author":"Carlsson","year":"2014","journal-title":"BMJ"},{"key":"2025120718571697500_djaf271-B3","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/cncr.25474","article-title":"Balancing the harms and benefits of early detection of prostate cancer","volume":"116","author":"van Leeuwen","year":"2010","journal-title":"Cancer"},{"key":"2025120718571697500_djaf271-B4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"2025120718571697500_djaf271-B5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1741-7015-12-26","article-title":"Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen","volume":"12","author":"Vickers","year":"2014","journal-title":"BMC Med"},{"key":"2025120718571697500_djaf271-B6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/cncr.25568","article-title":"Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50","volume":"117","author":"Lilja","year":"2011","journal-title":"Cancer"},{"key":"2025120718571697500_djaf271-B7","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.urology.2013.06.074","article-title":"Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng\/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort","volume":"82","author":"Weight","year":"2013","journal-title":"Urology"},{"key":"2025120718571697500_djaf271-B8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2015.01.009","article-title":"Improving the specificity of screening for lethal prostate cancer using prostate-specific antigen and a panel of kallikrein markers: a nested case-control study","volume":"68","author":"Stattin","year":"2015","journal-title":"Eur Urol"},{"key":"2025120718571697500_djaf271-B9","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.eururo.2018.02.016","article-title":"Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men","volume":"73","author":"Sjoberg","year":"2018","journal-title":"Eur Urol"},{"key":"2025120718571697500_djaf271-B10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/JU.0000000000003603","article-title":"Free PSA and clinically significant and fatal prostate cancer in the PLCO screening trial","volume":"210","author":"Yim","year":"2023","journal-title":"J Urol"},{"key":"2025120718571697500_djaf271-B11","doi-asserted-by":"crossref","first-page":"c4521","DOI":"10.1136\/bmj.c4521","article-title":"Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study","volume":"341","author":"Vickers","year":"2010","journal-title":"BMJ"},{"key":"2025120718571697500_djaf271-B12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025120718571697500_djaf271-B13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/00365590310008839","article-title":"Validity of a population-based cancer register in Sweden\u2014an assessment of data reproducibility in the South-East Region Prostate Cancer Register","volume":"37","author":"Sandblom","year":"2003","journal-title":"Scand J Urol Nephrol"},{"key":"2025120718571697500_djaf271-B14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/ije\/dys068","article-title":"Cohort profile: the national prostate cancer register of Sweden and prostate cancer data Base Sweden 2.0","volume":"42","author":"Van Hemelrijck","year":"2013","journal-title":"Int J Epidemiol"},{"key":"2025120718571697500_djaf271-B15","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"key":"2025120718571697500_djaf271-B16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/clinchem\/41.8.1115","article-title":"Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum","volume":"41","author":"Mitrunen","year":"1995","journal-title":"Clin Chem"},{"key":"2025120718571697500_djaf271-B17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1373\/clinchem.2005.050641","article-title":"Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C","volume":"52","author":"Ulmert","year":"2006","journal-title":"Clin Chem"},{"key":"2025120718571697500_djaf271-B18","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","article-title":"Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication","volume":"28","author":"Vickers","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025120718571697500_djaf271-B19","author":"R Core Team","year":"2021"},{"key":"2025120718571697500_djaf271-B20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J"},{"key":"2025120718571697500_djaf271-B21","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"JOSS"},{"key":"2025120718571697500_djaf271-B22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00008469-200112000-00003","article-title":"The Malm\u00f6 Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants","volume":"10","author":"Manjer","year":"2001","journal-title":"Eur J Cancer Prev"},{"key":"2025120718571697500_djaf271-B23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JU.0000000000001007","article-title":"Prespecified 4-kallikrein marker model at age 50 or 60 for early detection of lethal prostate cancer in a large population based cohort of asymptomatic men followed for 20 years","volume":"204","author":"Vertosick","year":"2020","journal-title":"J Urol"},{"key":"2025120718571697500_djaf271-B24","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025120718571697500_djaf271-B25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/01.ju.0000169262.18000.8a","article-title":"Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans","volume":"174","author":"Whittemore","year":"2005","journal-title":"J Urol"},{"key":"2025120718571697500_djaf271-B26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eururo.2011.11.007","article-title":"Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population","volume":"61","author":"Orsted","year":"2012","journal-title":"Eur Urol"},{"key":"2025120718571697500_djaf271-B27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2018.08.032","article-title":"Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in Black men","volume":"75","author":"Preston","year":"2019","journal-title":"Eur Urol"},{"key":"2025120718571697500_djaf271-B28","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1002\/cncr.23885","article-title":"Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng\/mL and lower","volume":"113","author":"Walz","year":"2008","journal-title":"Cancer"},{"key":"2025120718571697500_djaf271-B29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2005.04.015","article-title":"Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng\/ml: systematic review and meta-analysis","volume":"48","author":"Roddam","year":"2005","journal-title":"Eur Urol"},{"key":"2025120718571697500_djaf271-B30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/bju.15417","article-title":"Association between one-time prostate-specific antigen (PSA) test with free\/total PSA ratio and prostate cancer mortality: a 30-year prospective cohort study","volume":"128","author":"Lundgren","year":"2021","journal-title":"BJU Int"},{"key":"2025120718571697500_djaf271-B31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2340\/1651-226X.2025.41334","article-title":"Considerable decline in prostate cancer mortality in Nordic countries after 2000","volume":"64","author":"Kv\u00e5le","year":"2025","journal-title":"Acta Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf271\/64328393\/djaf271.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/12\/2591\/64328393\/djaf271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/12\/2591\/64328393\/djaf271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T23:57:26Z","timestamp":1765151846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/12\/2591\/8258937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,19]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf271","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,19]]}}}